Designing the Ecosystem for CGT Success
This proceedings eBook, developed in partnership with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures perspectives and lessons from The Cell Summit ’26 and extends the conversation beyond the meeting itself. The post Designing the Ecosystem for CGT Success appeared first on GEN - Genetic Engineering and Biotechnology News .
In July 2026, BioLife Solutions hosted the second annual Cell Summit in Cincinnati, Ohio. The summit aimed to gather leaders from the cell and gene therapy (CGT) sector to discuss challenges standing between scientific innovation and successful patient treatment. CGT has already achieved remarkable scientific breakthroughs, but the next hurdle is scaling these therapies for widespread patient use.
Mature healthcare industries have demonstrated that coordinated scale can be achieved through interconnected systems of production, supply, distribution, clinical delivery, reimbursement, infrastructure, standards, and oversight. However, CGT is still in the process of building this system. At the summit, experts from various backgrounds, including scientists, therapy developers, clinicians, treatment centers, technology providers, and manufacturing experts, examined the CGT pathway from multiple angles.
The discussions revealed that scale is an operating system, encompassing manufacturing, reimbursement, care delivery, logistics, partnerships, data, governance, evidence, and trust. Each link in the CGT pathway is interdependent, and a breakdown in any one link can hinder patient access and weaken the commercial model. Successful CGT therapies require proper identification and referral of eligible patients, collection or manufacturing of the product, timely delivery to treatment centers, and effective patient reception.
Additionally, the therapy must deliver the intended outcome, and the economics must support repeatable delivery for subsequent patients. If one link fails, patients may wait, and the commercial model may suffer. The summit emphasized that collaboration is fundamental to CGT advancement, as a therapy's success extends beyond the manufacturing site to reaching and benefiting the patient as intended.
The proceedings eBook, co-published with GEN and Cincinnati Children’s Hospital Applied Gene and Cell Therapy Center, captures insights from the summit and encourages continued discussion to design the CGT ecosystem deliberately, much like the therapies themselves.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
